Dilvas Tablet is classified as an angiotensin-converting enzyme (ACE) inhibitor medication. It’s primarily prescribed for managing hypertension (high blood pressure) and heart failure, and may be recommended following a heart attack. This medication also helps reduce the risk of future cardiovascular events like heart attacks and strokes.
Dilvas Tablet can be administered as monotherapy or combined with other medications. For optimal absorption, it should be taken on an empty stomach. Consistent daily dosing at the same time is recommended to maintain therapeutic effectiveness. Patients should continue treatment even when asymptomatic or after achieving blood pressure control, as discontinuation may worsen the condition. While generally well-tolerated for chronic use, this medication requires ongoing medical supervision.
Complementary lifestyle modifications can enhance treatment efficacy, including: regular physical activity, weight management, smoking cessation, moderated alcohol consumption, and sodium restriction as directed by your physician. Common adverse effects may include hypotension, persistent cough, hyperkalemia, fatigue, generalized weakness, and dizziness – typically transient in nature. Consult your healthcare provider if side effects persist or cause concern.
Prior to initiating therapy, disclose any renal or hepatic impairment. Pregnancy and breastfeeding require special consideration and medical consultation. Regular monitoring of renal function, blood pressure, and serum potassium levels is recommended during treatment.
THERAPEUTIC INDICATIONS
- Management of essential hypertension
- Secondary prevention of cardiovascular events (myocardial infarction and stroke)
- Chronic heart failure therapy
CLINICAL BENEFITS
Antihypertensive Action
Frequently Reported Adverse Reactions
- Postural hypotension
- ACE inhibitor-associated cough
- Asymptomatic hyperkalemia
- Asthenia
- General malaise
- Vertigo
ADMINISTRATION GUIDELINES
PHARMACOLOGICAL MECHANISM
Medical Disclaimer:
Reviews
There are no reviews yet